Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/340204
Type: Artigo
Title: Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response
Author: Resende, Uanderson
Cabello, Cesar
Ramalho, Susana Oliveira Botelho
Zeferino, Luiz Carlos
Abstract: Breast cancer with pathological non-complete response (non-pCR) after neoadjuvant chemotherapy (NAC) has a worse prognosis. Despite Neo-Bioscore has been validated as an independent prognostic model for breast cancer submitted to NAC, non-pCR carcinoma was not assessed in this setting.MethodsThis is a retrospective trial that included women with localized breast cancer who underwent NAC and had non-pCR carcinoma in surgical specimen between 01/01/2013 to 12/31/2015 with a three-year follow-up. Survival analysis was performed by Kaplan-Meier estimator and hazard ratio (HR) set by log-rank test for the primary and secondary endpoints, respectively Disease-Free Survival (DFS) and Overall Survival (OS). According to Neo-Bioscore, the proposed prognostic model named Clustered Neo-Bioscore was classified into low (0-3), low-intermediate (4-5), high-intermediate (6) and high (7) risk. The prognostic accuracy for recurrence risk was assessed by time-dependent receiver operating characteristic (time-ROC) methodology. Multivariate Cox regression assessed the menopausal status, histological grade, Ki-67, estrogen receptor, HER2, tumor subtype, pathological and clinical stages. Confidence interval at 95% (CI95%) and statistical significance at set 2-sided p-value less than 0.05 were adopted.ResultsAmong the 310 women enrolled, 267 patients (86.2%) had non-pCR carcinoma presenting size T3/T4 (63.3%), node-positive axilla (74.9%), stage III (62.9%), Ki-6720% (71.9%) and non-luminal A (78.3%). Non-pCR carcinoma presented worse DFS-3y (HR=3.88, CI95%=1.18-11.95) but not OS-3y (HR=2.73, CI95%=0.66-11.40). Clustered Neo-Bioscore discerned the recurrence risk for non-pCR carcinoma: low (DFS-3y=0.86; baseline), low-intermediate (DFS-3y=0.70; HR=2.61), high-intermediate (DFS-3y=0.13, HR=14.05), and high (DFS-3y=not achieved; HR=22.19). The prognostic accuracy was similar between Clustered Neo-Bioscore and Neo-Bioscore (0.76 vs 0.78, p>0.05). Triple-negative subtype (HR=3.6, CI95%=1.19-10.92) and pathological stages II (HR=5.35, CI95%=1.19-24.01) and III (HR=6.56, CI95%=1.29-33.32) were prognoses for low-intermediate risk, whereas pathological stage III (HR=13.0, CI95%=1.60-106.10) was prognosis for low risk.ConclusionsClustered Neo-Bioscore represents a novel prognostic model of non-pCR carcinoma undergoing NAC with a more simplified and appropriate score pattern in the assessment of prognostic factors
Subject: Carcinoma
Terapia neoadjuvante
Country: Reino Unido
Editor: Springer Nature
Rights: Aberto
Identifier DOI: 10.1186/s12885-019-5812-0
Address: https://bmccancer.biomedcentral.com/articles/10.1186/s12885-019-5812-0
Date Issue: 2019
Appears in Collections:FCM - Artigos e Outros Documentos
CAISM - Artigos e Outros Documentos

Files in This Item:
File Description SizeFormat 
000471859100012.pdf1.37 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.